Serum malondialdehyde correlates with therapeutic efficiency of high activity antiretroviral therapies (HAART) in HIV-1 infected children

Free Radical Research

Volumn 36, Issue 3, 2002, Pages 341-344

  Jareo, Enrique J ^a   Romá, Joaqun ^b   Romero, Belén ^a   Marcdn, Nuria ^a   Muriach, Mara ^a   Johnsen, Siv ^c   Bosch Morell, Francisco ^c   Marselou, Lena ^a   Romero, Francisco J ^c  

^a HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

^c UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

Author keywords

Children; HAART; HIV; Malondialdehyde; Oxidative stress

Indexed keywords

ANTIRETROVIRUS AGENT; BIOLOGICAL MARKER; DIDANOSINE; LAMIVUDINE; MALONALDEHYDE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD LEVEL; CHILD; CHILD CARE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNITY; LACTIC ACIDOSIS; LIPODYSTROPHY; MORBIDITY; MORTALITY; MYOPATHY; NEUROPATHY; NONHUMAN; OXIDATIVE STRESS; RESPIRATORY FAILURE; TREATMENT OUTCOME; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; CHILD; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV-1; HUMANS; MALONDIALDEHYDE; OXIDATIVE STRESS;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0036521851     PISSN: 10715762     EISSN: None     Source Type: Journal    
DOI: 10.1080/10715760290019363     Document Type: Article

References (25)

1. Sönnerborg, A., Carlin, G., Akerlund, B. and Jarstrand, C. (1988) "Increased production of malondialdehyde in patients with HIV infection", Scand. J. Infect. Dis, 20, 287-290.
2. Buhl, R., Holroyd, K.J., Mastrangeli, A., Cantin, A.M., Jaffe, H.A., Wells, F.B., Saltini, C. and Crystal, R.G. (1989) "Systemic glutathione deficiency in symptom-free HIV-seropositive individuals", Lancet iii, 1294-1298.
3. Staal, F.J.T., Roederer, M., Israelski, D.M., Bubp, J., Mole, L.A., McShane, D., Deresinski, S.C., Ross, W., Jussman, H. and Raju, P.A. (1992) "Intracellular glutathione levels in T cell subsets decrease in HIV infected individuals", AIDS Res. Hum. Retroviruses 8, 305-311.
4. Malvy, D.J.M., Richard, M.J., Arnaud, J., Favier, A. and Amédee-Manesme, O. (1994) "Relationship of plasma malondialdehyde, vitamin E and antioxidant micronutrients to human immunodeficiency virus-1 seropositivity", Clin. Chim. Acta 224, 89-94.
5. McLemore, J.L., Beeley, R, Thorton, K., Morrisroe, K., Blackwell, W. and Dasgupta, A. (1998) "Rapid automated determination of lipid hydroperoxide concentrations and total antioxidant status of serum samples from patients infected with HIV: elevated lipid hydroperoxide concentrations and depleted total antioxidant capacity of serum samples", Am. J. Clin. Pathol. 109, 268-273.
6. Nabel, G. and Baltimore, D. (1987) "An inducible transcription factor activates expression of human immunodeficiency virus in T cells", Nature 326, 711-713.
7. Schreck, R., Rieber, P. and Bauerle, P.A. (1991) "Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κB transcription factor and HIV-1", EMBO J. 10, 2247-2258.
8. Jareño, E.J., Bosch-Morell, F., Fernández-Delgado, R., Donat, J. and Romero, F.J. (1998) "Serum malondialdehyde in HIV seropositive children", Free Radic. Biol, Med. 24, 503-506.
9. Jareño, E.J., Bosch-Morell, F., Fernández-Delgado, R., Donat, J. and Romero, F.J. (1998) "Serum malondialdehyde in HIV seropositive children negatively correlates with CD4+ lymphocytes count", Biofactors 8, 129-132,
10. Romero F.J., Jareño E.J., Bosch-Morell F., Donat J., Fernández-Delgado R., (1999). "Correlation of the serum concentration of malondialdehyde, a lipid peroxidation product, with the clinical status of HIV seropositve children. "In Proceedings of the Seventh European Conference on Clinical Aspects and Treatment of HIV Infection. Monduzzi Editori, Bologna, pp 177-180.
11. Fahey, J.L., Taylor, J.M.G., Detels, R., Hofmann, B., Melmed, R., Nishanian, P. and Giorgi, J.V. (1990) "The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1", N. Engl. J. Med. 322, 166-172.
12. CDC(1994) "Revised classification system for human immunodeficiency virus infection in children less than 13 years of age", MMWR 43(RR-12), 1-10.
13. Mellors, J.W., Rinaldo, C.R., Gupta, P., White, R.M., Todd, J.A. and Kingsley, L.A. (1996) "Prognosis in HIV-1 infection predicted by the quantity of virus in plasma", Science 272, 1167-1170.
14. Mofenson, L.M., Korelitz, J., Meyer, III, W.A., Bethel, J., Rich, K., Pahwa, S., Moye, Jr., J., Nugent, R. and Read, J. (1997) "The relationship between serum Human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and along term mortality risk in HIV-1 infected children", J. Infect. Dis. 175, 1029-1038.
15. Mcintosh, K., Shevitz, A., Zaknun, D., Kornegay, J., Chatis, P., Kartas, N. and Burchett, S.K. (1996) "Age- and time-related changes in extracellular viral load in children vertically infected by human immunodeficiency virus", Pediatr. Infect. Dis. J. 15, 1087-1091.
16. Ho, D.D. (1995) "Time to hit HIV, early and hard", N. Engl. J. Med. 333, 450-451.
17. Cohen, O.J. and Fauci, A.S. (1998) "HIV/AIDS in 1998- Gaining the upper hand?", J. Am. Med. Assoc. 280, 87-88.
18. Powderly, W.G., Landay, A. and Lederman, M.M. (1998) "Recovery of the immune system with antiretroviral therapy. The end of opportunism?", J. Am. Med. Assoc. 280, 72-77.
19. Palella, F.J.J., Delaney, K.M., Moorman, A.C., Loveless, M.O., Fuhrer, J., Satten, G.A., Aschman, D.J. and Holmber, S.D. (1998) "Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection", N. Engl. J. Med. 338, 853-860.
20. García de la Asunción, J., del Olmo, M.L., Sastre, J., Millán, A., Pellín, A., Pallardó, F.V. and Viña, J. (1998) "AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria", J. Clin. Investig. 102, 4-9.
21. CDC(1998) "Guidelines for the use of antiretroviral agents in pediatric HIV infection", MMWR(RR4), 1-43.
22. Romero, M.J., Bosch-Morell, F., Romero, B., Rodrigo, J.M., Serra, M.A. and Romero, F.J. (1998) "Serum malondialdehyde: possible use for the clinical management of chronic hepatitis C patients", Free Radic. Biol. Med. 25, 993-997.
23. Romero, F.J., Bosch-Morell, F., Romero, M.J., Jareño, E.J., Romero, B., Marín, N. and Romá, J. (1998) "Lipid peroxidation products and antioxidants in human disease", Environ. Health Perspect. 5(Suppl. 5), 1229-1234.
24. Koh, Y.H., Park, Y.S., Takahashi, M., Suzuki, K. and Taniguchi, N. (2000) "Aldehyde reductase gene expression by lipid peroxidation end products, MDA and HNE, Free Radic. Res. 33, 739-746.
25. Moyle, G. (2000) "Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity", Clin. Ther. 22, 911-936.